Home » Stocks » BIIB

Biogen Inc. (BIIB)

Stock Price: $269.44 USD -0.68 (-0.25%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $268.80 -0.64 (-0.24%) Jan 22, 7:56 PM
Market Cap 41.46B
Revenue (ttm) 14.26B
Net Income (ttm) 5.08B
Shares Out 156.90M
EPS (ttm) 30.38
PE Ratio 8.87
Forward PE 10.38
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $269.44
Previous Close $270.12
Change ($) -0.68
Change (%) -0.25%
Day's Open 270.34
Day's Range 268.48 - 272.71
Day's Volume 691,169
52-Week Range 236.26 - 355.63

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
The Motley Fool - 1 day ago

The Oracle of Omaha may give these brand-name companies the boot from Berkshire Hathaway's portfolio.

Other stocks mentioned: CHTR, JPM, WFC
Seeking Alpha - 1 day ago

Treating The Causes Of Alzheimer's Disease: The Case For Anavex 2-73

Other stocks mentioned: AVXL, BHVN, LLY, SAVA
Investopedia - 4 days ago

These are the healthcare stocks with the best value, fastest growth, and most momentum for February 2021.

Other stocks mentioned: BIO, CVS, HZNP, MRNA, PODD, QDEL, TDOC
Zacks Investment Research - 1 week ago

Apple (AAPL) is collaborating with Biogen to test whether the Apple Watch and iPhone can collect and transmit biometric data on cognitive performance.

Other stocks mentioned: AAPL
Newsfile Corp - 1 week ago

New York, New York--(Newsfile Corp. - January 11, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Biogen Inc. (NASDAQ: BIIB) alle...

Seeking Alpha - 1 week ago

Biogen Inc. (BIIB) Management Presents at 39th Annual J.P. Morgan Healthcare Conference (Transcript)

Benzinga - 1 week ago

Exact Sciences (NASDAQ: EXAS) shares are trading higher after the company issued fourth-quarter sales guidance above analyst estimates. Exact Sciences is a molecular diagnostics company focuse...

Other stocks mentioned: EXAS, LLY
GlobeNewsWire - 1 week ago

NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securiti...

Market Watch - 1 week ago

Shares of Biogen Inc. gained 5.6% in trading on Monday after another drugmaker shared positive clinical data about an experimental Alzheimer's disease treatment that is similar to a Biogen the...

Other stocks mentioned: LLY
Seeking Alpha - 1 week ago

Biogen has an impressive portfolio of assets, and the company is heavily focused on R&D with major drugs like Aducanumab. The company's impressive drug portfolio has the potential to make 2021...

Newsfile Corp - 1 week ago

New York, New York--(Newsfile Corp. - January 11, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Biogen Inc. ("Biogen" or the ...

Benzinga - 1 week ago

Biogen Inc (NASDAQ: BIIB), which has a fairly solid neurology-focused pipeline, announced Monday a collaboration with tech giant Apple Inc (NASDAQ: AAPL). What Happened: Cambridge, Massachuset...

Other stocks mentioned: AAPL
Newsfile Corp - 1 week ago

New York, New York--(Newsfile Corp. - January 11, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired secur...

GlobeNewsWire - 1 week ago

CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced a new virtual research study, in collaboration with Apple, to investigate the role Apple Watch an...

Accesswire - 1 week ago

NEW YORK, NY / ACCESSWIRE / January 10, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded co...

Other stocks mentioned: QSR, SPLK
Newsfile Corp - 2 weeks ago

New York, New York--(Newsfile Corp. - January 9, 2021) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion ...

Business Wire - 2 weeks ago

LOS ANGELES--(BUSINESS WIRE)---- $BIIB #investors--The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen, Inc. (BIIB)

Business Wire - 2 weeks ago

NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB) and c...

PRNewsWire - 2 weeks ago

BENSALEM, Pa., Jan. 8, 2021 /PRNewswire/ -- Law Offices of Howard G. Smith reminds investors of the upcoming January 12, 2021 deadline to file a lead plaintiff motion in the case filed on beha...

Newsfile Corp - 2 weeks ago

New York, New York--(Newsfile Corp. - January 8, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securi...

GlobeNewsWire - 2 weeks ago

CAMBRIDGE, Mass., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the first patient has been treated in the global clinical study, RESPOND. The Phase 4 study ...

Newsfile Corp - 2 weeks ago

New York, New York--(Newsfile Corp. - January 7, 2021) -  Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion...

Business Wire - 2 weeks ago

NEW YORK--(BUSINESS WIRE)-- #biogen--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the Unite...

GuruFocus - 2 weeks ago

As the Covid-19 vaccines from Pfizer (NYSE:PFE), BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA) continue to be distributed throughout the U.S. and internationally to doctors, nurses, the eld...

Other stocks mentioned: CVS, HUM, UHS
PRNewsWire - 2 weeks ago

LOS ANGELES, Jan. 6, 2021 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise ac...

Newsfile Corp - 2 weeks ago

New York, New York--(Newsfile Corp. - January 6, 2021) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion ...

Newsfile Corp - 2 weeks ago

New York, New York--(Newsfile Corp. - January 4, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB). Such investors ...

PRNewsWire - 2 weeks ago

LOS ANGELES, Jan. 4, 2021 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming January 12, 2021 deadline to file a lead plaintiff motion in the class action fi...

PRNewsWire - 2 weeks ago

NEW YORK, Jan. 4, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities cl...

The Motley Fool - 2 weeks ago

Warren Buffett's investing track record is impressive -- but he's not always right.

Other stocks mentioned: KHC, SNOW
Seeking Alpha - 3 weeks ago

Wide-Moat Stocks On Sale - The January 2021 Heat Map

Other stocks mentioned: BK, BTI, GSK, IMBBY, INTC, LMT, MO, MRK, RHHBY, SNY
GuruFocus - 3 weeks ago

If you want to increase your likelihood of finding stocks that could beat the market, one method is to choose stocks that rank highly on the "Magic Formula" criteria.

Other stocks mentioned: DLX, GILD
The Motley Fool - 3 weeks ago

Today's the final day for tax-loss harvesting in 2020.

Other stocks mentioned: AAL, ACB, NKLA, OXY
GlobeNewsWire - 3 weeks ago

LOS ANGELES, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming January 12, 2021 deadline to file a lead plaintiff motion in the class acti...

Accesswire - 3 weeks ago

NEW YORK, NY / ACCESSWIRE / December 28, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you ...

Other stocks mentioned: ICPT, KNDI
Newsfile Corp - 4 weeks ago

New York, New York--(Newsfile Corp. - December 26, 2020) - Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB). Such investor...

The Motley Fool - 4 weeks ago

These biotech stocks could sink or soar following some important approval decisions slated for the new year.

Other stocks mentioned: BLUE, TGTX
Newsfile Corp - 1 month ago

New York, New York--(Newsfile Corp. - December 22, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Biogen Inc. (NASDAQ: BIIB) all...

Newsfile Corp - 1 month ago

New York, New York--(Newsfile Corp. - December 22, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired secu...

Newsfile Corp - 1 month ago

Boston, Massachusetts--(Newsfile Corp. - December 22, 2020) - The Thornton Law Firm announces that a class action lawsuit has been filed on behalf of investors of Biogen Inc. (NADSAQ: BIIB). I...

24/7 Wall Street - 1 month ago

Over halfway through the trading day on Tuesday, and the broad markets have yet to make up their minds.

Other stocks mentioned: PEAK, IQV, LESL
PRNewsWire - 1 month ago

BENSALEM, Pa., Dec. 22, 2020 /PRNewswire/ -- Law Offices of Howard G. Smith reminds investors of the upcoming January 12, 2021 deadline to file a lead plaintiff motion in the case filed on beh...

Accesswire - 1 month ago

NEW YORK, NY / ACCESSWIRE / December 22, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded c...

Other stocks mentioned: BABA, PINS
Forbes - 1 month ago

We believe that Biogen stock, a biotechnology company focused on treatments for neurological diseases, is a good buying opportunity at the present time. BIIB stock trades near $250 currently a...

GlobeNewsWire - 1 month ago

CAMBRIDGE, Mass., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the European Commission (EC) has approved a new intramuscular (IM) injection route of admini...

GlobeNewsWire - 1 month ago

NEW YORK, Dec. 20, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. (“Biogen” or the “Company”) (NASDAQ:  BIIB).   Such investors are advise...

The Motley Fool - 1 month ago

Each company has suffered a clinical failure recently, but this team-up could do good things for both.

The Motley Fool - 1 month ago

This biotech giant is getting desperate to generate sales growth. Should investors be hopeful for a potential turnaround?

The Motley Fool - 1 month ago

The company isn't standing still while its Alzheimer's drug is up in the air.

Reuters - 1 month ago

Biogen Inc has agreed to pay $22 million to resolve U.S. allegations that it illegally used two charities that help cover Medicare patients' out-of-pocket drug costs as a means to pay them kic...

About BIIB

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treati... [Read more...]

Industry
Drug Manufacturers-General
IPO Date
Sep 16, 1991
CEO
George Scangos
Employees
7,400
Stock Exchange
NASDAQ
Ticker Symbol
BIIB
Full Company Profile

Financial Performance

In 2019, Biogen's revenue was $14.38 billion, an increase of 6.88% compared to the previous year's $13.45 billion. Earnings were $5.89 billion, an increase of 32.90%.

Financial Statements

Analyst Forecasts

According to 33 analysts, the average rating for Biogen stock is "Hold." The 12-month stock price forecast is 291.38, which is an increase of 8.14% from the latest price.

Price Target
$291.38
(8.14% upside)
Analyst Consensus: Hold